Bevacizumab(Beijing Science Sun)

Phalguni Deswal Detailed Phase II results are expected in the first half of 2024. Image Credit: Net Vector / Shutterstock. 4D Molecular Therapeutics (4DMT) has provided a timeline for the development of 4D-150 to treat wet age-related macular degeneration (wet AMD). 4D-150 is an intravitreal vector-based therapy developed using the therapeutic vector evolution platform as an adeno-associated virus vector to deliver an anti-VEGF transgene that expresses both aflibercept and a VEGF-C inhibitory RNAi, to treat wet AMD. Recommended Reports Reports LOA and PTSR Model - Recombinant Human Erythropoietin Injection in Anemia in Chronic Kidney Disea... GlobalData Reports LOA and PTSR Model - Gene Therapy to Target BCMA for Relapsed and Refractory Multiple Myeloma GlobalData View all Companies Intelligence Bayer AG 4D Molecular Therapeutics Inc Cytiva Chugai Co.,Ltd. Regeneron GmbH View all According to GlobalData , the current market for wet AMD treatment is dominated by anti-VEGF therapies Roche and Novartis ’ Lucentis (ranibizumab), Roche and Chugai ’s Avastin (bevacizumab), and Regeneron and Bayer ’s Eylea (aflibercept) . GlobalData is the parent company of Pharmaceutical Technology. The multicentre, randomised Phase I/II PRISM trial (NCT05197270) has completed enrolment for the open-label Phase II dose expansion stage. The trial will assess the safety and efficacy of 4D-150 at two dose levels in 50 patients. The interim reported data demonstrated no treatment-related adverse reactions. Detailed results are expected in the first half of 2024, as per the company’s press release . 4DMT plans to start Phase III trial discussions with the US’ FDA in Q4 2023, with a trial update planned for Q1 2024. 4DMT CEO David Kirn also provided updates on their other pipeline candidates, stating: “We believe that 4D-150’s differentiated profile has the potential to also drive rapid enrolment in our diabetic macular oedema (DME) programme, and we expect to enrol our first patient in the Phase II SPECTRA trial in Q3 2023. “We remain committed to the advancement of our large market ophthalmology product candidates, including 4D-150 for wet AMD and DME, as well as 4D-175 for geographic atrophy.” There have been an increasing number of trials for wet AMD , with GlobalData forecasting the AMD market to expand to $19.8bn in 2028. The other Phase I/II pipeline drugs include a single-dose aerosol drug ( 4D-710 ) for cystic fibrosis, a gene vector ( 4D-110 ) for choroideremia, gene therapy ( 4D-125 ) for X-linked retinitis pigmentosa. Along with 4D-310, gene therapy, for the treatment of classic (severe) Fabry disease cardiomyopathy, that has received a Fast Track Designation from the US FDA in 2020. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva . Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content. Free Whitepaper Optimise your cell therapy process: a guide to cell thawing Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer. This guide addresses how cell thawing has historically developed into the new techniques used today, along with the physical and biological implications of key metrics and components such as warming rate and ice structure. Also included are reviews of key studies from scientific literature and a consideration of the interactions between cooling and warming rates, as applicable to cell and gene therapies. By Cytiva Thematic By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy